10-Q: Orchestra BioMed Boosts Liquidity Amid Rising R&D Costs

Orchestra BioMed reports increased net losses in Q3 2025, but secures significant new financing and initiates a pivotal clinical trial for Virtue SAB, while terminating its Terumo agreement.

Summary

• Net loss for the nine months ended September 30, 2025, increased by 31% to $58.9 million, compared to $44.9 million for the same period in 2024.
• Total revenue for the nine months ended September 30, 2025, grew by 8% to $2.565 million, up from $2.385 million in 2024, driven by partnership revenue.
• Research and development expenses surged by 30% to $41.4 million for the nine months ended September 30, 2025, primarily due to increased support for the BACKBEAT study and the Virtue Trial.
• Selling, general and administrative expenses increased by 9% to $19.6 million for the nine months ended September 30, 2025.
• Cash and cash equivalents, along with marketable securities, totaled $95.8 million as of September 30, 2025, an increase from $66.8 million at December 31, 2024.
• The company successfully raised $62.6 million in gross proceeds from a public offering and private placements in August 2025.
• The Terumo Agreement for Virtue SAB was terminated on October 24, 2025, with Orchestra BioMed receiving a $10.0 million fee and retaining rights for other vascular indications, while granting Terumo a Right of First Refusal.
• Patient enrollment commenced in the Virtue SAB in the Treatment of Coronary ISR Trial (Virtue Trial) on October 27, 2025, targeting 740 patients across up to 75 U.S. centers, with completion planned for mid-2027.
• A convertible loan of $20.0 million from Medtronic was agreed upon on July 31, 2025, with funding expected on April 27, 2026, converting to a revenue share credit upon FDA approval of an AVIM-enabled device.
• A Royalty Purchase Agreement with Ligand Pharmaceuticals, signed July 31, 2025, provided $20.0 million upfront (August 4, 2025) and a conditional $15.0 million payable on May 1, 2026, in exchange for tiered royalty payments on AVIM Therapy and Virtue SAB revenues.
• The 2024 Loan and Security Agreement with Hercules Capital was amended to delay amortization payments to July 1, 2027 (or January 1, 2028) and increase discretionary borrowing capacity by $15.0 million to $35.0 million.

Sentiment

Score: 5

Explanation: While the company reported increased net losses and R&D expenses, indicating a challenging financial period, it successfully secured substantial new financing and initiated a pivotal clinical trial. The termination of the Terumo agreement is a mixed event, removing a revenue stream but providing cash and strategic flexibility. The overall sentiment is neutral-to-slightly-positive due to improved liquidity and clinical progress, balanced against rising losses and ongoing funding needs.

Positives

• Secured significant new financing totaling over $100 million from public offerings, private placements, a royalty purchase agreement, and a convertible loan agreement, substantially improving liquidity.
• Initiated the pivotal Virtue SAB in the Treatment of Coronary ISR Trial (Virtue Trial), a key step towards regulatory approval for a significant product candidate.
• Successfully terminated the Terumo Agreement, receiving a $10.0 million fee and retaining global rights for Virtue SAB in non-coronary vascular indications, providing strategic flexibility.
• Extended the cash runway to fund operations into the fourth quarter of 2027, providing a longer period for clinical development.
• Amended the Hercules loan agreement to delay amortization payments and increase discretionary borrowing, easing short-term debt obligations and increasing financial flexibility.
• Established a 2025 New Hire Inducement Plan, reserving 950,000 shares to attract and retain key talent, which is crucial for a growing biomedical company.

Negatives

• Net loss increased by 31% to $58.9 million for the nine months ended September 30, 2025, indicating continued and growing operating losses.
• Research and development expenses increased by 30% to $41.4 million, reflecting a high burn rate for clinical trials and product development.
• Interest expense shifted from income to a net expense of $385,000 for the nine months ended September 30, 2025, primarily due to new debt arrangements.
• The termination of the Terumo Agreement means the company will not earn previously anticipated development and regulatory milestone payments under that agreement.
• Product revenue from FreeHold's retractors decreased by 3% for the nine months ended September 30, 2025, indicating a slight decline in sales volume for this product.
• The company has an accumulated deficit of $368.8 million as of September 30, 2025, highlighting its history of operating losses.
• The issuance of common stock and pre-funded warrants in August 2025, along with other equity-linked financings, resulted in significant dilution for existing shareholders.

Risks

• Uncertainty of clinical trial outcomes, including the BACKBEAT global pivotal study and the Virtue Trial, which could impact regulatory approvals and commercialization goals.
• Uncertainty of additional funding, as the company expects to incur substantial operating losses and may require further capital raises beyond current estimates.
• Reliance on third parties for manufacturing, marketing, and sales of product candidates, which introduces dependency and potential supply chain issues.
• Ability to protect or enforce intellectual property, unpatented trade secrets, know-how, and other proprietary technology.
• Potential for serious adverse events or undesirable side effects from product candidates, which could halt clinical development or regulatory approval.
• Economic conditions that may adversely affect business, financial condition, and stock price.
• The sale of common stock pursuant to the Resale Registration Statement may result in a decline in the value of the Company Common Stock due to increased supply and potential selling pressure from early investors.
• Failure to achieve certain enrollment milestones for the BACKBEAT clinical study by January 1, 2027, could lead to increased royalty payment percentages to Ligand Pharmaceuticals.

Future Outlook

The company anticipates that its current cash, marketable securities, and committed future proceeds (including $20.0 million from the Medtronic Loan Agreement and $15.0 million from Ligand) are sufficient to fund operations into the fourth quarter of 2027. It expects to incur substantial operating losses for the foreseeable future due to increased spending on flagship product candidates, clinical study costs, and expanded research and development activities for AVIM-enabled Therapy and Virtue SAB programs. The company cannot assure completion of enrollment for the BACKBEAT study (mid-2026 target) or the Virtue Trial (mid-2027 target) within anticipated timeframes and may need to seek additional liquidity earlier than current estimates.

Management Comments

• We expect to continue to incur significant losses for the foreseeable future.
• We anticipate that our Cash and cash equivalents, Marketable securities, proceeds received subsequent to September 30, 2025 but prior to the filing of this Quarterly Report on Form 10-Q, expected future proceeds from contractual financing commitments and other potential future proceeds described below are sufficient to fund our operations into the fourth quarter of 2027.
• We cannot provide assurance that we will be able to complete enrollment of the BACKBEAT study or the Virtue Trial in the timeframes we anticipate.

Industry Context

Orchestra BioMed operates in the highly competitive biomedical device industry, focusing on high-impact technologies through risk-reward sharing partnerships. Its flagship product candidates, AVIM Therapy for hypertension and Virtue SAB for atherosclerotic artery disease, target large global markets. The company's strategy of partnering with established medical device companies like Medtronic and previously Terumo, allows it to leverage their commercialization capabilities while focusing on development. The termination of the Terumo agreement and subsequent initiation of its own pivotal trial for Virtue SAB, while retaining rights, indicates a shift towards potentially more direct control over its assets or seeking new partnerships. The significant capital raises are typical for a company in the clinical development stage, where substantial R&D investment is required before commercialization.

Comparison to Industry Standards

• The company's accumulated deficit of $368.8 million and continued operating losses are common for early-stage biomedical companies heavily invested in R&D, similar to many biotech and med-tech startups prior to product commercialization and profitability.
• The 22.5% effective annual interest rate on the Royalty Purchase Agreement with Ligand Pharmaceuticals is relatively high, reflecting the risk profile associated with future royalty streams from uncommercialized products, which can be higher than traditional debt financing rates for more established companies or lower-risk assets.
• The target enrollment of 740 patients for the Virtue Trial and 500 patients for the BACKBEAT study are substantial for pivotal clinical trials in the medical device space, comparable to the scale of studies required for FDA approval of novel therapies.
• The company's reliance on a partnership-enabled business model, as seen with Medtronic, is a common strategy in the medical device industry for smaller innovators to access larger market reach and established infrastructure, similar to collaborations seen between smaller biotechs and large pharmaceutical companies.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceeding that would have a material adverse effect on its business, operating results, or financial condition.

Related Party Transactions

• Entities associated with RTW Investments, LP (beneficially owned ~21% of common stock) purchased Pre-Funded Warrants exercisable for 3,636,363 shares in the August 2025 public offering.
• Perceptive Life Sciences Master Fund, Ltd (beneficially owned ~12% of common stock) purchased Pre-Funded Warrants exercisable for 1,500,000 shares in the August 2025 public offering.
• Medtronic (beneficially owned ~15% of common stock) purchased 4,209,709 shares of common stock in private placements and entered into the Medtronic Loan Agreement for a $20.0 million convertible loan.
• Covidien Group S..r.l., an affiliate of Medtronic, purchased 4,077,427 shares of Company Common Stock on August 4, 2025, and an additional 132,282 shares on August 28, 2025.
• The company's strategic investments include preferred shares of Vivasure Medical Limited, a privately-held related party, with a carrying value of $2.5 million as of September 30, 2025.

Stakeholder Impact

• **Shareholders**: Experience significant dilution from recent equity offerings and potential future capital raises. The increase in net loss and R&D expenses could negatively impact investor sentiment, but extended liquidity and clinical progress offer long-term potential. The Series A Preferred Stock has liquidation preference over common stock.
• **Employees**: Benefit from the new 2025 New Hire Inducement Plan, offering equity awards to attract and retain talent. Continued R&D investment supports job stability in development roles.
• **Customers**: Potential future customers for AVIM Therapy and Virtue SAB could benefit from the advancement of these product candidates through clinical trials towards commercialization.
• **Partners (Medtronic, Ligand)**: Medtronic's collaboration is strengthened by the amended agreement and convertible loan, aligning interests in AVIM Therapy. Ligand benefits from the royalty purchase agreement, gaining a share of future product revenues. Terumo's role has shifted from a distribution partner to holding a Right of First Refusal for Virtue SAB in coronary indications.
• **Creditors (Hercules Capital)**: The amendment to the 2024 LSA provides more favorable repayment terms, delaying amortization and increasing discretionary borrowing capacity, which reduces immediate pressure on the company's cash flow.

Next Steps

• Continue enrollment and execution of the BACKBEAT global pivotal study, with enrollment completion currently estimated for mid-2026.
• Continue enrollment and execution of the Virtue SAB in the Treatment of Coronary ISR Trial (Virtue Trial), with enrollment completion currently planned for mid-2027.
• Receive the $20.0 million funding from the Medtronic Loan Agreement on April 27, 2026, subject to customary closing conditions.
• Receive the conditional $15.0 million Second Installment from Ligand Pharmaceuticals on May 1, 2026, provided certain conditions are met.
• Publicly disclose primary endpoint data from the U.S. IDE study for ISR, which is a condition for conversion of Series A Preferred Stock and impacts the ROFR period with Terumo.
• Potentially engage in negotiations with Terumo if a Third-Party Proposal for Virtue SAB in coronary artery disease is received during the ROFR Period.
• Manage the transition of emerging growth company status, expected on December 31, 2025, which will impact financial accounting standards compliance.

Key Dates

Recommendation

Orchestra BioMed Holdings, Inc. is a high-growth, high-risk biomedical company. While the significant capital raises (over $100 million) and the initiation of the pivotal Virtue Trial are positive developments that extend the company's liquidity runway into Q4 2027, the company continues to report substantial and increasing net losses driven by high R&D expenses. The termination of the Terumo agreement, while providing immediate cash and retaining rights, introduces uncertainty regarding future commercialization pathways for Virtue SAB. The stock is highly speculative, with future success heavily dependent on positive clinical trial outcomes and successful commercialization, which are years away. For a seasoned investor, a 'Hold' recommendation is appropriate, acknowledging the improved liquidity and clinical progress, but also the inherent risks, ongoing losses, and potential for further dilution. Investors should monitor clinical trial progress, regulatory milestones, and future financing activities closely.

Keywords

Biomedical, Medical Device, Clinical Trials, AVIM Therapy, Virtue SAB, Hypertension, Atherosclerotic Artery Disease, ISR, SEC Filing, 10-Q, Financing, Stock Option Plan, Corporate Governance, Medtronic, Ligand Pharmaceuticals, Terumo